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migration. Sphingosine kinases (Sphks) mediate the formation of S1P, whereas S1P lyase mediates the degradation of S1P [11] . S1P is the ligand for five G-protein-coupled receptors (GPCRs), named S1PR1-5, with distinct signalling pathways that regulate immunity, chemotaxis, angiogenesis, vascular maturation and other important biological pathways [12] . S1P and its receptors play a key role in autoimmune diseases such as multiple sclerosis, sickle cell disease, inflammatory bowel disease, asthma and rheumatoid arthritis [11, [13] [14] [15] [16] .
Our previous study found that S1P plays a crucial role in the process of C5a-mediated neutrophil activation in AAV [17] . Blockade of S1P could attenuate C5a-induced ANCA-mediated neutrophil activation. S1PR antagonists could downregulate C5a-induced neutrophil migration and significantly attenuate the C5a-primed ANCA-induced neutrophil respiratory burst and degranulation, with an inhibition rate of approximately 60%. In addition, it was found that in an endotoxin-induced lung inflammatory injury animal model, Sphk1 plays a key role in regulating the balance between the expression of C5a receptors CD88 and C5a receptor-like 2 (C5L2) [18] . These data collectively suggested that S1P is a crucial factor in C5a-mediated neutrophil activation.
In recent years, accumulating evidence has suggested an important role of S1P and S1PRs in regulating endothelial barrier integrity. Li et al. [19] found that different doses of S1P could induce distinct biological effects in endothelial cells and that the final barrier regulating the efficacy of S1P depends on the balance of expression and activation of different S1PRs in endothelial cells. In our current study, the plasma levels of S1P and the expression of S1PRs in kidneys were investigated in AAV patients and their correlation with clinical and histopathological parameters was analysed.
M A T E R I A L S A N D M E T H O D S

Patients and samples
In total, 32 patients with active AAV at initial onset, diagnosed at Peking University First Hospital from 2010 to 2015, were enrolled in our study. Plasma samples from these patients were collected before the initiation of immunosuppressive treatment. Plasma samples of 20 patients in the remission stage from the above-mentioned 32 patients were also collected at their regular ambulatory visits. All patients met the criteria of the 2012 Chapel Hill Consensus Conference definition for AAV [1] . Patients with secondary vasculitis or with comorbid renal diseases such as lupus nephritis (LN) and IgA nephropathy were excluded. Patients with other autoimmune diseases, such as Graves' disease and rheumatoid arthritis, were also excluded. All types of infection, particularly urinary infection, were also excluded from clinical and laboratory data. Plasma samples of 20 healthy blood donors, 26 patients with chronic renal failure (CRF) and 20 patients with LN were collected as either normal controls or disease controls. The blood samples of the patients and controls were centrifuged at 1000 g for 10 min at 4 C within 30 min after collection. Then they were stored at À80 C in aliquots until use. Repeated freeze/thaw cycles were avoided.
Disease activity of AAV was assessed according to the Birmingham vasculitis activity score (BVAS) [20] . Remission was defined as the 'absence of disease activity attributable to active disease qualified by the need for ongoing stable maintenance immunosuppressive therapy', as previously described [21] . In total, 24 of the above-mentioned 32 AAV patients received renal biopsy at diagnosis and before the initiation of immunosuppressive treatment. Six renal tissues were obtained from the normal part of nephrectomized (because of renal carcinoma) kidneys and were used as normal controls; they were determined to be normal using light microscopy, immunofluorescence and electron microscopy. Written informed consent was obtained from each participant. This research was conducted in compliance with the Declaration of Helsinki and approved by the ethics committee of Peking University First Hospital.
Detection of S1P by enzyme-linked immunosorbent assay (ELISA) S1P was analysed by ELISA using a commercial kit (Echelon, Salt Lake City, UT, USA). The assay was conducted according to the manufacturer's instructions. A 96-well plate was coated with S1P in advance and blocked to reduce non-specific binding. After mixing the S1P standards and plasma samples with the anti-S1P antibody, we added the mixture to the plate. The antibody competes for binding to S1P bound to the plate or in the plasma sample. Following a 1-h incubation and five washes of the plate, we added streptavidin-horseradish peroxidase (HRP) to the plate. After an additional incubation, we added 3,3 0 ,5,5 0 -tetramethylbenzidine (TMB) substrate. We stopped the reaction by adding sulfuric acid. We then measured the absorbance at 450 nm within 15 min. The concentration of S1P in the plasma samples was determined by comparsion to the standard curve.
Quantification of C5a, ICAM-1 and NETs
Circulating concentrations of C5a and ICAM-1 were analysed using commercial ELISA kits according to the manufacturer's instructions (Quidel, San Diego, CA, USA; R&D Systems, Minneapolis, MN, USA). As an indirect way to assess neutrophil extracellular traps (NETs), cell-free DNA was quantified using a Quant-iT PicoGreen DNA quantification kit (Invitrogen, Carlsbad, CA, USA) in accordance with the manufacturer's instructions.
Renal histology
Renal histology of AAV patients was evaluated according to the previous standardized protocol [22] [23] [24] . The presence of glomerular lesions, including glomerulosclerosis, crescents and fibrinoid necrosis, were calculated as a percentage of the total number of glomeruli in a biopsy. Tubular and interstitial lesions were scored semi-quantitatively on the basis of the percentage of the tubulointerstitial compartment that was affected: interstitial fibrosis (-for 0%, þ for 0-50% and þþ for > 50%), interstitial infiltrate (-for 0%, þ for 0-20%, þþ for 20-50% and þþþ for > 50%) and tubular atrophy (-for 0%, þ for 0-50% and þþ for > 50%).
Detection of S1PR expression in kidneys by immunohistochemistry
The specimens were deparaffinized overnight before staining. They were then further deparaffinized in xylene and rehydrated through graded ethanol. Endogenous peroxidase activity was quenched with 3% hydrogen peroxide at room temperature for 30 min. Antigen retrieval was performed by heating the slides in citrate buffer (0.01 M, pH 6.0) in an 800W microwave oven for 2 min and then at 200W one for 8 min. The slides were then cooled to room temperature and washed in phosphate buffered saline (PBS). Non-specific staining was blocked by incubating the specimens with 3% bovine serum albumin (BSA) in PBS at 37 C for 1 h. After removing BSA without washing, primary antibodies were added (anti-S1PR1-5; Table 1 ) and then incubated for 16 h at 4 C. As a negative control, specimens were incubated with 3% BSA instead of primary antibodies. Secondary antibodies (Dako, Copenhagen, Denmark) were incubated with the specimens at 37 C for 30 min. Next, the specimens were developed in fresh hydrogen peroxide plus 3-3 0 -diaminobenzidine tetrahydrochloride solution for 1 min. Eventually the specimens were incubated with haematoxylin and then dehydrated through graded alcohol and xylene. The expression of each S1PR was observed under a light microscope.
We used the Image-Pro Plus analysis software (version 6.0; Media Cybernetics, Dallas, TX, USA) to evaluate the renal staining of S1PR1-5. Positive signals were quantified as the mean optical density (integrated option density/area). All the glomeruli in a section at Â400 were observed blindly as a semiquantitive assessment of renal immunohistochemical staining.
Co-localization of S1PRs with CD31 and elastase
To determine which cell types displayed increased S1PR expression, we performed double immunofluorescence staining of S1PRs and specific markers of endothelial cells and neutrophils. Endothelial cells were identified by immunofluorescence staining with primary antibodies against CD31 (sc53411, Santa Cruz, Dallas, TX, USA; ab32457, Abcam, Cambridge, MA, USA). Neutrophils were identified by immunofluorescence staining with antibodies against neutrophil elastase (NE; gwb-8f72c4, GenWay, San Diego, CA, USA; Abcam, ab131260, Cambridge, MA, USA). The renal specimens were stored at À80 C until use. Non-specific binding sites were blocked by incubating the specimens with 3% BSA in PBS. The specimens were then incubated with the mixture of primary antibodies overnight at 4 C. After washing the specimens with PBS, we incubated the specimens with the secondary antibody mixture of Alexa Fluor (AF488)-labelled donkey anti-rabbit IgG (1:200; Jackson ImmunoResearch, West Grove, PA, USA) and cyanin 3 (Cy3)-labelled donkey anti-mouse IgG (1:200; Jackson ImmunoResearch) at 37 C for 1 h. After washing with PBS, the specimens were stained with 4 0 ,6-diamidino-2-phenylindole (DAPI) and eventually mounted with Mowiol. For negative controls, the mixture of primary antibodies was replaced with 3% BSA. We captured confocal images using a Zeiss LSM 710 confocal microscope (Zeiss, Jena, Thueringen, Germany) and we exported the images using ZEN 2012 (blue edition) microscopy software. Furthermore, to corroborate our assumption that S1PRs are expressed by the glomerular endothelium, we performed double immunofluorescence staining in different endothelial cells, including human umbilical vein endothelial cells (HUVECs; ScienCell Research Laboratories, Carlsbad, CA, USA), human glomerular endothelial cells (HGECs; ScienCell Research Laboratories) and human pulmonary microvascular endothelial cells (HPMECs; ScienCell Research Laboratories). Additionally, we performed double immunofluorescence staining in neutrophils from both healthy donors and AAV patients. The neutrophils were isolated as previously described [8] .
Statistical analysis
For normally distributed data, differences of quantitative parameters between groups were analysed using the t-test and means 6 standard deviation (SD) were presented as descriptive statistics. For non-normally distributed data, differences of quantitative parameters between groups were analysed using the non-parametric test and median and interquartile range (IQR) were presented as descriptive statistics. For two parametric variables, correlation analysis between two continuous variables was performed using Pearson's correlation. For two nonparametric variables or one non-parametric variable with one parametric variable, correlation analysis between two continuous variables was performed using Spearman's rank correlation. If P < 0.05, differences were considered statistically significant. Data analysis was performed with SPSS version 13.0 (SPSS, Chicago, IL, USA).
R E S U L T S
Demographic and general data
Of the 32 patients with active AAV, 13 (40.6%) were male and 19 (59.4%) were female, with an average age of 59.1 6 12.0 years at diagnosis. Thirty patients were perinuclear ANCA (pANCA)-positive, and these sera all recognized MPO; two patients were cytoplasmic ANCA (cANCA)-positive, and these sera all recognized PR3. The level of initial serum creatinine was 302.6 6 164.4 (range 72.2-668.3) lmol/L. The level of BVAS in the 32 patients in active stage was 22.1 6 6.2 and zero in the 20 patients in remission (Table 2) .
Among the 26 patients with CRF, 16 (61.5%) were male and 10 (38.5%) were female, with an age of 55.7 6 13.1 years at sampling. The level of serum creatinine was 347.1 6 115.9 (range 172.0-638.8) lmol/L. The main underlying diseases of the CRF patients were IgA nephropathy, hypertensive renal injury and diabetic nephropathy.
Among the 20 patients with LN, 9 (45.0%) were male and 11 (55.0%) were female, with an age of 51.0 6 15.6 years at diagnosis. The level of initial serum creatinine was 317.1 6 135.2 (range 83.0-644.3) lmol/L.
Plasma levels of S1P
Plasma samples from the 32 patients with AAV in active stage, 20 patients with AAV in remission, 20 healthy blood donors, 26 CRF patients and 20 LN patients were collected. The plasma levels of S1P in AAV patients in active stage and AAV patients in remission were significantly higher compared with normal controls (1789.48 6 521.10 versus 817.72 6 562.74 nmol/L, P < 0.001; 1462.48 6 498.31 versus 817.72 6 562.74 nmol/L, P < 0.001, respectively; Figure 1 ). The plasma levels of S1P were also significantly higher in AAV patients in active stage than those in AAV patients in remission (1789.48 6 521.10 versus 1462.48 6 498.31 nmol/L, P < 0.05). In addition, the plasma S1P levels of AAV patients in active stage were significantly higher than those in CRF patients and LN patients (1789.48 6 521.10 versus 1480.18 6 443.26 nmol/L, P < 0.05; 1789.48 6 521.10 versus 1348.93 6 788.77 nmol/L, P < 0.05, respectively).
We then compared the circulating levels of S1P in the 20 AAV patients who had sequential plasma samples from both active stage and remission. The plasma levels of S1P were significantly higher in active stage than in remission (1871.63 6 527.16 versus 1462.48 6 498.31 nmol/L; P < 0.001). Eighteen of these 20 patients exhibited a decrease in the plasma level of S1P in remission compared with the level observed in active stage, while only 2 patients exhibited a slight increase in the plasma level of S1P in remission compared with that in active stage (Figure 2) .
To adjust for serum creatinine values, we further compared the plasma S1P levels of 11 AAV patients who had plasma samples from both active stage and remission with similar serum creatinine values (239.04 6 177.81 versus 232.245 6 168.66lmol/L, P ¼ 0.422) and we found that the levels of plasma S1P in patients in active stage were still significantly higher than those in remission (1733.41 6 529.06 versus 1419.54 6 558.69 nmol/L, P ¼ 0.012). We compared the plasma S1P levels of 11 patients with active AAV and 11 CRF patients with similar serum creatinine values (254.99 6 175.57 versus 258.54 6 178.29 lmol/L, P ¼ 0.388) as well and found that the levels of plasma S1P in active AAV patients were significantly higher than those in CRF patients Collectively, these results indicated that the elevation of circulating S1P levels was independent of renal dysfunction.
Among the 32 patients with AAV in active stage, correlation analysis showed that the plasma levels of S1P correlated with the initial serum creatinine levels (r ¼ 0.502, P ¼ 0.003) and C5a (r ¼ 0.462, P ¼ 0.023) and inversely correlated with the estimated glomerular filtration rate (eGFR; r ¼ À0.358, P ¼ 0.044; Figure 3 ). However, the S1P level was not associated with ICAM-1 (r ¼ 0.001, P ¼ 0.995) or NETs (r ¼ 0.044, P ¼ 0.877). No significant correlation was found between the level of S1P and BVAS (r ¼ À0.107, P ¼ 0.560) or CRP (r ¼ 0.129, P ¼ 0.549).
Immunohistochemistry for S1PRs
We performed studies on the renal histopathology of 24 AAV patients in the active phase. In the renal specimens of AAV patients, immunohistochemical staining revealed prominent expression of S1PRs in proximal tubules, distal tubules and collecting ducts (Figure 4) . S1PR1-5 staining in the renal specimens of AAV patients was evaluated by the Image-Pro Plus analysis software (version 6.0). Compared with normal controls, the mean optical density of S1PR2-5 in AAV patients in glomeruli was significantly higher (0.089 6 0.028 versus 0.030 6 0.007, P < 0.001; 0.025 6 0.009 versus 0.013 6 0.002, P < 0.001; 0.063 6 0.018 versus 0.025 6 0.004, P < 0.001; 0.018 6 0.007 versus 0.010 6 0.002, P < 0.01, respectively). However, no significant difference was observed for the mean optical density of S1PR1 in glomeruli between AAV patients and normal controls (0.021 6 0.009 versus 0.015 6 0.003; P ¼ 0.095; Figure 5 ).
Among the AAV patients, correlation analysis suggested that the mean optical density of S1PR2 correlated with levels of BVAS and CRP (r ¼ 0.477, P ¼ 0.019; and r ¼ 0.560, P ¼ 0.046, Mean optical density of S1PR4 in glomeruli of AAV patients and healthy controls. (E). Mean optical density of S1PR5 in glomeruli of AAV patients and healthy controls. As the major effector cells in the pathogenesis of AAV, neutrophil activation eventually causes endothelial cell damage [3, 25, 26] . Therefore, double immunofluorescence staining was performed to further determine which types of cells displayed increased S1PR expression. It was found that S1PR1-5 could co-localize with CD31 in the glomeruli (Figure 7) , whereas S1PR1, 4 and 5 could co-localize with NE ( Figure 8) . Collectively, we determined that S1PR1-5 were expressed on endothelial cells in the glomeruli, while S1PR1, 4 and 5 were expressed on neutrophils. Furthermore, to corroborate this result, we performed double immunofluorescence staining in different endothelial cells, including HUVECs, HGECs and HPMECs, and in neutrophils. It was found that S1PR1-5 could co-localize with CD31 in HUVECs, HGECs and HPMECs ( Supplementary  Figures S1-S3 ), while S1PR1, 4 and 5 could co-localize with NE in neutrophils (Supplementary Figures S4-S5 ).
D I S C U S S I O N
S1P is a small molecule sphingolipid metabolite that regulates diverse cellular processes including survival, proliferation, adhesion and migration. S1P has been implicated in the pathogenesis of a wide range of inflammatory conditions, with decreased levels observed in sepsis, dengue and cerebral malaria [27] [28] [29] . [30] found that S1P levels are elevated in type 2 diabetes mellitus. Watson et al. [31] found that paediatric patients with SLE, particularly those with LN, have elevated S1P levels. Our previous study found that S1P is a crucial factor in the process of C5a-mediated neutrophil activation in AAV [17] . However, S1P and its receptors have not been investigated in AAV.
In this study, it was found that the plasma levels of S1P in AAV patients in active stage were significantly higher than those in AAV patients in remission. The difference was significant even after adjusting for renal function. Further correlation analysis showed that circulating S1P levels correlated with the initial serum creatinine levels and inversely correlated with the eGFR in AAV patients. These results suggest that the plasma levels of S1P might reflect the renal involvement and, to some extent, disease activity of AAV. However, the underlying mechanism requires further study. In addition, we found that the plasma S1P levels of AAV patients in active stage were significantly higher than those in CRF patients with comparable renal function, which indicated that the elevated S1P level in AAV patients is not an issue of renal dysfunction. It was also found that compared with normal controls, S1P remained elevated in AAV patients in remission, which may be explained by tissue damage or low-grade inflammatory activity despite clinical remission.
The five types of S1P receptors, S1PR1-5, all have high affinity for S1P [11] . In the present study, double staining of S1PR1-5 and CD31 suggested that S1PR1-5 were expressed on endothelial cells in the glomeruli of AAV. Recent studies have revealed that the balance of the expression and activation of different S1PRs in endothelial cells plays a key role in regulating vascular integrity. S1P at physiological concentrations preserves endothelial barrier function by binding to S1PR1, whereas excessive S1P induces endothelial malfunction by activating S1PR2 [19] . S1PR3 promotes leukocyte rolling by mobilizing endothelial P-selectin, while leukocyte rolling is increased in endothelial-specific S1PR1 knockout mice [32] . In the present study, it was found that the expression level of S1PR2-5 in AAV patients in glomeruli was significantly higher than that in normal controls, whereas no significant difference was observed for the expression level of S1PR1. Therefore, the balance between S1PR expression is broken in AAV patients, which might participate in the pathogenesis of AAV. Recent studies have demonstrated that the S1PRs can differentially regulate small guanosine triphosphatases (GTPases) of the Rho family, especially Rho and Rac, which are important in cytoskeletal rearrangement, and participate in the maintenance/disruption of cell barrier integrity [33, 34] . Whether similar mechanisms exist in AAV requires further confirmation.
In our study, correlation analysis revealed that S1PR expression correlates with both inflammatory and coagulation parameters. Accumulating evidence has demonstrated that C5a plays a crucial role in AAV [4-7, 35, 36] . On the one hand, C5a primes neutrophils for ANCA-induced respiratory burst and degranulation. On the other hand, C5a-primed ANCA-activated neutrophils release TF-expressing MPs and NETs, which subsequently activate the coagulation system and generate thrombin [37, 38] . Our previous study further demonstrated that S1P is a crucial factor in C5a-mediated neutrophil activation [17] , indicating a potential role of S1P in both the inflammation system and the coagulation system. Under homeostatic conditions, high levels of S1P in circulation are a result of its release from red blood cells and endothelial cells, whereas platelets may only release S1P during platelet activation and clotting [39] [40] . Furthermore, studies have found that the S1P concentration gradient between circulation and tissues is essential for cellular trafficking of immune cells. Persistent proinflammatory challenges of the vessel wall during atherosclerosis or acute vascular injury are characterized by activation of the coagulation cascade and platelets, which release large amounts of S1P, thereby increasing local S1P concentrations. This may play a key role in directing immune cells to local injury sites, thereby directly linking the coagulation system to the inflammatory system [41] [42] [43] . Therefore, we speculate that S1P might act as a link between inflammation and blood coagulation in AAV.
In conclusion, in AAV patients the circulating S1P levels were elevated and the renal expression of S1PR2-5 was upregulated. The levels of circulating S1P and the renal expression of S1PR were associated with the renal involvement and disease activity of AAV.
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